QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Romiplostim, Thrombopoietin-Receptor Biology, ITP, and Product Pharmacovigilance

Test your understanding of the concepts covered by Romiplostim: thrombopoietin receptor biology, immune thrombocytopenia, and product pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A patient has a sudden platelet increase after a recent dose adjustment. Which interpretation is most appropriate?

The increase proves that the prior dose was ineffective. The result should be interpreted in the context of the expected delayed response and serial platelet trajectory. The dose should always be increased further because a higher count is the treatment goal. The increase demonstrates that the autoimmune diagnosis was incorrect.

Question 2 of 10 A patient's platelet count falls after corticosteroids are tapered while romiplostim dosing remains unchanged. What is the most appropriate interpretation?

The fall must be caused by romiplostim because its dose did not change. The timing of the concomitant-treatment change could explain the platelet trajectory and must be considered in causality assessment. The fall proves anti-romiplostim antibodies are present. The fall demonstrates that platelet production is independent of immune activity.

Question 3 of 10 What is the most appropriate pharmacovigilance interpretation of thrombocytopenia and bleeding soon after romiplostim discontinuation?

It is unrelated because the patient is no longer exposed. It may reflect recurrence of the underlying ITP after loss of receptor stimulation and requires a post-discontinuation timeline. It proves that romiplostim permanently damaged megakaryocytes. It demonstrates neutralisation of endogenous TPO in every case.

Question 4 of 10 Which feature distinguishes romiplostim from endogenous thrombopoietin and reduces the theoretical risk of neutralising native TPO?

Romiplostim does not bind MPL. Romiplostim has no amino-acid sequence homology with endogenous TPO in its receptor-binding peptides. Romiplostim suppresses endogenous TPO production. Romiplostim is administered only by the oral route.

Question 5 of 10 Why should a medication-error report be retained for aggregate surveillance even if no adverse event occurred?

Because every medication error confirms product causality. Because repeated errors may reveal a preventable system weakness before clinical harm accumulates. Because medication errors are always more serious than adverse drug reactions. Because an error without harm must be coded as thrombosis.

Question 6 of 10 Which information is most important for distinguishing a prescribed dose from the dose actually delivered in a suspected medication-error case?

The patient's age alone. The product's ATC code alone. The weight used, reconstitution and dilution steps, calculated volume, and administration records. The most recent platelet count without preparation details.

Question 7 of 10 Which statement best explains why increased platelet production can benefit a patient whose autoimmune platelet destruction continues?

The production increase can exceed the rate of platelet clearance, raising the circulating count. Romiplostim prevents all immune recognition of platelets. Autoimmune destruction stops automatically once MPL is activated. New platelets are immune to all forms of clearance.

Question 8 of 10 Why can a medication error involving romiplostim's preparation be clinically significant even when the numerical dose error appears small?

Romiplostim is dosed in kilograms of product rather than micrograms. Weight-based microgram dosing and very small administration volumes can make dilution or measurement errors proportionally important. All preparation errors are automatically harmless because the product is biological. The product has no dose-response relationship.

Question 9 of 10 Which description best captures romiplostim's therapeutic strategy in primary ITP?

It directly eliminates platelet autoantibodies from the circulation. It increases platelet production to compensate for immune-mediated platelet loss. It blocks Fc receptors on splenic macrophages. It permanently corrects the underlying autoimmune disorder.

Question 10 of 10 Which case narrative would provide the strongest basis for assessing a report of loss of romiplostim effect?

A single current platelet count and the patient's sex. The product name without dose or administration information. Serial platelet counts linked to dose changes, preparation details, concomitant ITP treatments, intercurrent illness, and marrow findings. Only the date on which the patient first reported fatigue.

QPPV.com

Knowledge Assessment: Romiplostim, Thrombopoietin-Receptor Biology, ITP, and Product Pharmacovigilance

Cookie Settings